Humanigen, Inc. (HGEN): Price and Financial Metrics


Humanigen, Inc. (HGEN): $1.64

-0.13 (-7.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HGEN POWR Grades


  • Growth is the dimension where HGEN ranks best; there it ranks ahead of 65.44% of US stocks.
  • HGEN's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • HGEN's current lowest rank is in the Stability metric (where it is better than 3.54% of US stocks).

HGEN Stock Summary

  • HGEN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.06% of US stocks.
  • As for revenue growth, note that HGEN's revenue has grown 1,052.24% over the past 12 months; that beats the revenue growth of 99.06% of US companies in our set.
  • The volatility of Humanigen Inc's share price is greater than that of 99.46% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Humanigen Inc are KZIA, GOVX, ZYME, NVAX, and IVA.
  • Visit HGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.humanigen.com.

HGEN Valuation Summary

  • In comparison to the median Healthcare stock, HGEN's price/sales ratio is 4632.16% higher, now standing at 537.1.
  • Over the past 104 months, HGEN's price/earnings ratio has gone up 1.2.
  • Over the past 104 months, HGEN's price/sales ratio has gone up 531.9.

Below are key valuation metrics over time for HGEN.

Stock Date P/S P/B P/E EV/EBIT
HGEN 2021-08-31 537.1 22.5 -4.9 -4.5
HGEN 2021-08-30 543.5 22.8 -5.0 -4.5
HGEN 2021-08-27 563.3 23.6 -5.2 -4.7
HGEN 2021-08-26 577.5 24.2 -5.3 -4.8
HGEN 2021-08-25 570.1 23.9 -5.2 -4.8
HGEN 2021-08-24 559.4 23.5 -5.1 -4.7

HGEN Growth Metrics

    Its 5 year price growth rate is now at 45.71%.
  • Its 5 year cash and equivalents growth rate is now at -98.84%.
  • The 3 year net cashflow from operations growth rate now stands at 78.14%.
Over the past 67 months, HGEN's revenue has gone up $3,595,000.

The table below shows HGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 3.595 -184.045 -236.649
2021-09-30 2.87 -175.481 -235.404
2021-06-30 1.834 -151.022 -199.416
2021-03-31 0.798 -105.07 -152.635
2020-12-31 0.312 -69.853 -89.535
2020-09-30 0 -46.707 -59.266

HGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HGEN has a Quality Grade of C, ranking ahead of 29.47% of graded US stocks.
  • HGEN's asset turnover comes in at 0.019 -- ranking 371st of 682 Pharmaceutical Products stocks.
  • ZSAN, ARMP, and AGRX are the stocks whose asset turnover ratios are most correlated with HGEN.

The table below shows HGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.019 1 9.745
2021-03-31 0.011 1 9.024
2020-12-31 0.006 1 6.758
2020-09-30 0.000 NA 5.896
2020-06-30 0.000 NA 3.998
2020-03-31 0.000 NA 1.549

HGEN Price Target

For more insight on analysts targets of HGEN, see our HGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.13 Average Broker Recommendation 1.67 (Moderate Buy)

HGEN Stock Price Chart Interactive Chart >

Price chart for HGEN

HGEN Price/Volume Stats

Current price $1.64 52-week high $18.68
Prev. close $1.77 52-week low $1.62
Day low $1.62 Volume 2,616,100
Day high $1.85 Avg. volume 1,476,784
50-day MA $2.11 Dividend yield N/A
200-day MA $3.76 Market Cap 115.84M

Humanigen, Inc. (HGEN) Company Bio


Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.


HGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

HGEN Latest Social Stream


Loading social stream, please wait...

View Full HGEN Social Stream

Latest HGEN News From Around the Web

Below are the latest news stories about Humanigen Inc that investors may wish to consider to help them evaluate HGEN as an investment opportunity.

H.C. Wainwright Thinks Humanigen’s Stock is Going to Recover

In a report issued on February 10, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Humanigen (HGEN – Research Report), with a price target of $28.00. The company's shares closed last Monday at $1.82, close to its 52-week low of $1.80. According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -17.4% and a 24.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Humanigen is a Moderate Buy with an average price target of $21.33.

Christine Brown on TipRanks | February 15, 2022

Humanigen to Present at BIO CEO & Investor Conference

BURLINGAME, Calif. & DUBLIN & LONDON, February 11, 2022--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Yahoo | February 11, 2022

Humanigen Launches Managed Access Program for Lenzilumab

BURLINGAME, Calif. & DUBLIN & LONDON, February 10, 2022--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program ("LenzMAP™"). Clinigen Group plc ("Clinigen"), a global pharmaceutical Services and Products company, is implementing the program. Lenzilumab

Yahoo | February 10, 2022

Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France

BURLINGAME, Calif. & FONTENAY-SOUS-BOIS, France, February 09, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ and Cenexi, a French CDMO specializing in the formulation, analytical development, and manufacture of complex molecule drugs, announced a collaboration aimed at making Cenexi a preferred supplier of lenzilumab in France and the European Union. The initial st

Yahoo | February 9, 2022

What Kind Of Shareholders Own Humanigen, Inc. (NASDAQ:HGEN)?

Every investor in Humanigen, Inc. ( NASDAQ:HGEN ) should be aware of the most powerful shareholder groups. Institutions...

Yahoo | February 6, 2022

Read More 'HGEN' Stories Here

HGEN Price Returns

1-mo -33.06%
3-mo -46.75%
6-mo -47.35%
1-year N/A
3-year -71.48%
5-year -82.13%
YTD -55.91%
2021 -78.74%
2020 617.95%
2019 -30.36%
2018 73.91%
2017 -89.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4642 seconds.